je.st
news
Tag: prostate cancer
How red wine can reduce risk of lethal prostate cancer - International Scientific Forum on Alcohol Research Critique 226
2019-05-16 12:23:00| Daily beverage news and comment - from just-drinks.com
In an analysis from the Health Professionals Follow-up Study, investigators evaluated the relation of alcohol consumption in their over 45,000 study participants to the development of lethal prostate cancer. They related alcohol first to the overall risk of prostate cancer among all subjects, then focused on the 5,182 men who developed non-metastatic prostate cancer to judge their risk of developing lethal prostate cancer or mortality.
Tags: forum
international
research
red
How great is the risk of prostate cancer from alcohol consumption? - International Scientific Forum on Alcohol Research Critique 192
2016-09-12 12:25:00| Daily beverage news and comment - from just-drinks.com
Scientific research on the association of alcohol consumption with the risk of prostate cancer has been mixed.
Tags: on
forum
great
international
For J&J Prostate Cancer Is PARP For The Course
2016-04-07 23:45:50| Food - Topix.net
Johnson & Johnson addressed two issues with one relatively small $35m payment: its position in prostate cancer and absence from PARP inhibition. The big pharma group locked up one of just two unpartnered assets in this rejuvenated class and has chosen to focus its work in prostate cancer, where Zytiga might soon run out of market exclusivity.
Tags: the
cancer
prostate
prostate cancer
Pricey prostate cancer drug's makers targeted by Congress
2016-03-29 19:18:18| Biotech - Topix.net
This combo of file photos shows, from left: U.S. Reps. Lloyd Doggett and Peter Welch, and Sen. Bernie Sanders.
Tags: cancer
drugs
congress
targeted
Crown Bioscience To Commercialize University Of York's Prostate Cancer Models For Drug Development
2016-02-17 02:07:05| drugdiscoveryonline News Articles
Crown Bioscience Inc., a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has reached an agreement with UK’s University of York to exclusively license and commercialize the university’s unique collection of patient-derived xenograft (PDX) models for prostate cancer.
Tags: development
university
models
drug